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Background:  Vaccines  may  have  non-speciﬁc  effects.  An  observational  study  from  Guinea-Bissau  sug-
gested  that  oral  polio  vaccine  at birth  (OPV0)  provided  with  Bacillus  Calmette–Guérin  (BCG)  vaccine  was
associated  with  down-regulation  of the  immune  response  to BCG  vaccine  6  weeks  later.  Based  on  the
previous  ﬁnding,  we  wanted  to test  our a priori  hypothesis  that OPV  would  dampen  the  immune  response
to  BCG,  and  secondarily  to test  immune  responses  to other  antigens.
Methods:  The  study  was  conducted  at the  Bandim  Health  Project  in  Guinea-Bissau  in 2009–2010.  Infants
were  randomised  to  OPV0  + BCG  versus  BCG  alone  at birth,  and subsequently  randomised  to have  a  blood
sample  taken  at 2, 4 or 6  weeks  post-randomisation.  Excreted  levels  of  cytokines  (IL-2,  IL-5,  IL-10,  TNF-
and  IFN-)  were  measured  from  whole  blood  in  vitro  stimulations  with  a panel  of  recall  vaccine  antigens
(BCG,  PPD,  OPV),  mitogen  (PHA)  or  innate  agonists  (LPS,  Pam3cys,  PolyI:C).  Additionally,  we  measured  the
local  reaction  to BCG,  white  blood  cell  distribution,  C-reactive  protein  (CRP)  and retinol-binding  protein
(RBP).  Cytokine  production  was  analysed  as the  prevalence  ratios  of responders  above  the  median.
Results:  Blood  samples  from  430  infants  (209  OPV0  + BCG;  221  BCG  alone)  were  analysed.  There  were
no  strong  differences  in  effects  2, 4 and  6  weeks  post-randomisation  and  subsequent  analyses  were
performed  on  the pooled  data. As  hypothesised,  receiving  OPV0  + BCG  versus  BCG  alone  was  associated
with  signiﬁcantly  lower  prevalence  of  IFN-  responses  to  PPD  (prevalence  ratio  (PR):  0.84  (0.72–0.98))
and  reduced  IL-5 to  PPD  (PR:  0.78  (0.64–0.96)).  No  effects  were  observed  for  CPR,  RBP,  white  blood  cell
distribution,  or BCG scar  prevalence.
Conclusion:  The  results  corroborate  that OPV  attenuates  the  immune  response  to co-administered  BCG
at  birth.
ublis© 2014  The  Authors.  PAbbreviations: BCG, bacille Calmette-Guérin; BHP, Bandim Health Project; CI,
onﬁdence interval; CRP, C-reactive protein; DBS, dried blood spot; GMR, geometric
ean ratio; MUAC, mid-upper-arm-circumference; OPV, oral polio vaccine; PPD,
uriﬁed protein derivative (from Mycobacterium tuberculosis); PR, prevalence ratio;
BP, retinol-binding protein; RCT, randomised-controlled trial; TB, tuberculosis.
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1. Introduction
According to current vaccination policy, infants in high-risk
countries should receive oral polio vaccine at birth (OPV0) fol-
lowed by three doses in infancy [1]. The ﬁrst dose at birth is
usually given together with Bacillus Calmette-Guérin vaccine (BCG)
against tuberculosis (TB). Recently, OPV was temporarily miss-
ing in Guinea-Bissau. In this “natural experiment”, not receiving
OPV0 was  associated with increased infant male survival but a
weak tendency for increased mortality among females, indicating
that OPV0 may  have a sex-differential effect on infant mortality
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2]. The BCG given at birth is known to induce a potent pro-
nﬂammatory Th1-polarising IFN- response to puriﬁed protein
erivate from Mycobacterium tuberculosis (PPD) [3]. However, in
he “natural experiment” receiving OPV0 with BCG at birth was
ssociated with signiﬁcantly lower IFN- in response to PPD at
 weeks of age, and a moderately lower likelihood of developing
 BCG scar, suggesting that OPV0 may  dampen the response to
CG [4]. It could be speculated that part of the lower BCG vaccine
fﬁcacy in low-income countries [5] might be due to simultaneous
PV0.
To further investigate the heterologous effects of OPV, we car-
ied out a large randomised-controlled trial (RCT) testing the
ffects of providing OPV with BCG at birth on overall survival
Lund, submitted). The present sub-study aimed at investigating
he immunological effects of OPV together with BCG at birth on
he developing immune response at 2, 4 and 6 weeks of age,
ncluding innate and non-polio speciﬁc adaptive responses, non-
peciﬁc inﬂammation markers and immune cell distribution. Our a
riori hypothesis was that OPV would dampen the IFN- response
o PPD.
. Methods and materials
.1. Setting
The present immunological study was carried out within a larger
CT investigating the effects of providing OPV0 with BCG at birth on
nfant survival. The trial was conducted from July 2008 to October
011 at the Bandim Health Project (BHP), a health and demographic
urveillance system site covering six suburban districts of Bissau,
he capital of Guinea-Bissau, West Africa.
.2. Enrolment into the main trial
The trial has been described elsewhere (Lund, submitted; clin-
caltrials.gov: NCT00710983). In brief, newborns with no overt
llness or malformations, weighing ≥ 2.5 kg at enrolment and liv-
ng in the BHP study area were eligible for recruitment. Mothers
eceived oral and written information. Provided consent, the
other drew a randomisation number allocating her infant to
eceive OPV0 together with the BCG (OPV0 + BCG) or BCG alone
BCG). The BCG (Danish strain 1331, Statens Serum Institut, Copen-
agen, Denmark) was given intra-dermally in the upper left deltoid
egion while the trivalent OPV was administered as two drops
rally.
.3. Enrolment into the present sub-study
From 27 May  2009 to 7 April 2010, infants delivered on week-
ays at the maternity ward at the Simão Mendes National Hospital
nd randomised within the ﬁrst 7 days of life were invited to par-
icipate in the present immunological sub-study, excluding infants
elivered by caesarean section or twins. During the synchronised
est African Polio Immunisation Campaigns in March and April
010 some infants were not included (n = 32) (Fig. 1). Informed con-
ent was obtained according to the same procedure as the main
rial.
Measurements of weight, length, circumferences of abdomen,
ead and mid-upper-arm and axillary temperature of the infant,
nd axillary temperature of the mother were obtained at enrol-
ent. Subsequently, the infants were randomised to a follow-up
isit at home at 2, 4 or 6 weeks after enrolment. Infants who
eceived other vaccines before blood sampling were excluded from
he study (Fig. 1).2 (2014) 5949–5956
2.4. Follow-up
At the follow-up visit at 2, 4 or 6 weeks a blood sample was
collected, the mother was  interviewed about the health of her
infant; the mid-upper-arm circumference and axillary temperature
of the infant were measured; formation of scar or local reaction
at the site of BCG vaccination was  recorded (yes or no). Addi-
tionally, the main trial also recorded the presence and size of
BCG scar at 2, 6 and 12 months after enrolment on the same
infants. Size of the scar was  measured as the average of length
and width measured to nearest millimetre with a transparent
ruler.
2.5. Blood sampling and whole blood stimulations
At enrolment, a pre-vaccination baseline dried blood spot
(DBS) on ﬁlter paper was  collected by heel prick puncture for
measurement of retinol-binding protein (RBP) and C-reactive
protein (CRP). The ﬁlter paper was  dried in up-right position
overnight and stored with silica desiccant at −20 ◦C until anal-
ysis. At the follow-up visits, capillary blood was collected by
heel puncture into a heparinised tube for whole-blood stim-
ulation and in an EDTA-coated tube for differential counts,
respectively. A DBS for RBP and CRP measurements was
collected similarly to the baseline. A blood smear was  micro-
scopically inspected for malaria parasites. From collection to
processing, the heparinised blood was  kept at ambient tem-
perature; the EDTA-treated blood was  kept cold. All blood
samples were collected by the same trained nurse and trans-
ported to the National Laboratory within 4 h. The whole blood
stimulation assay was performed as previously described [6,7].
Brieﬂy, the heparinised blood was  diluted 1:10 with RPMI-
1640 medium (Invitrogen, Breda, Netherlands) supplemented
with 2 mM glutamate, 1 mM pyruvate, 100 IU penicillin and
100 g/ml streptomycin, and cultured at 37 ◦C with 5% CO2,
stimulated with lipopolysaccharide (LPS) (1 ng/ml, Sigma-Aldrich,
Zwijndrecht, Netherlands) [a Toll-like receptor (TLR)4 ago-
nist], (S)-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-
Cys-(S)-Ser-(S)-Lys4-OH,trihydrochloride (Pam3cys) (100 ng/ml,
Cayla-InvivoGen Europe, Toulouse, France) [a TLR2 agonist], anti-
gen puriﬁed protein derivative (PPD) of Mycobacterium tuberculosis
(10 g/ml, Statens Serum Institut, Copenhagen, Denmark), BCG
(Statens Serum Institut, ﬁnal concentration 1:100), trivalent
OPV (ﬁnal concentration 1:100) or phytohaemagglutinin (PHA)
(2 g/ml, Welcome Diagnostics, Dartford, UK) [a T cell mito-
gen]. Controls were medium alone cultures (referred as medium).
Supernatants were collected after one day (for LPS, Pam3cys and
medium1) or three days of incubation (for PPD, BCG, OPV, PHA,
poly I:C and medium3) and stored below minus 40 ◦C until cytokine
measurements.
2.6. Measurement of cytokine concentrations
Cytokine concentrations in supernatants were analysed at
Statens Serum Institut, Copenhagen, Denmark. IL-10 and TNF-
from day 1 supernatants stimulated with LPS and Pam3cys, and
IL-2, IL-5, IL-10, TNF- and IFN- from day 3 supernatants stimu-
lated with PPD, BCG, OPV, PHA and poly I:C were analysed using
Luminex cytokine kit and buffer reagent kit (BioSource, Camar-
illo, CA, USA) on a Luminex-200 cytometer (Luminex Corporation,
Austin, TX, USA) equipped with Bio-Plex Manager version 5.0
(Bio-Rad, Hercules, CA,USA). The assay was performed accord-
ing to the manufacturer’s instructions with slight modiﬁcations.
Brieﬂy, assays were performed in a 96-well U plate (NUNC,
Roskilde, Denmark) at room temperature. Mixes of beads were
incubated for 2 h with the test samples, the standard dilutions
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Fig. 1. Flow chart. Flow chart describing the selection, inclusion and exclusion of participants in the immunology study. Numbers in parentheses represent the randomisation
(  Natio
t ept ne
p
s
f
i
r
T
l
5
tOPV  + BCG/BCG alone). Newborns delivered outside weekends at the Simão Mendes
rial  during 27 May 2009 to 7 April 2010 were eligible in the immunology study, exc
rior  to blood sampling were not included.
eries, inter-assay controls and a blank in a ﬁnal volume of 50 l
or 2 h under continuous shaking. Beads were washed twice and
ncubated with biotinylated antibodies (25 l/well) for 1 h. After
emoval of excess antibodies, streptavidin-PE was added for 30 min.
he plate was then washed and analysed. The lower detection
imits of the assay deﬁned by the manufacturer were 6, 3, 5,
 and 10 g/ml for IL-2, IL-5, IL-10, IFN- and TNF-, respec-
ively.nal Hospital and enrolled within the ﬁrst 7 days of life in the randomised-controlled
onates delivered by caesarean section, and twins. Participants in an OPV campaign
2.7. Differential counts
Differential counts were performed on EDTA-treated blood by
using ABX Pentra 60 Hematology Analyzer (Horiba Diagnostic
Group, France). Due to logistic challenges in the laboratory, haema-
tological analyses were only conducted on blood samples collected
after 24 October 2009. Samples with an improper separation and
gating of the detected cell subsets as assessed by visual inspection
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Table 1
Background characteristics of study population.
Part A. At randomisation All Male Female
OPV+BCG n (%) BCG n (%) p OPV+BCG n (%) BCG n (%) p OPV+BCG n (%) BCG n (%) p
All 209 221 102 120 107 101
Males  102 (49%) 120 (54%) 0.25
Breastfeeding 206 (99%) 215 (99%) 0.97 100 (99%) 118 (100%) 0.28 106 (99%) 97 (98%) 0.52
Age  >1 day 15 (7%) 7 (3%) 0.42 11 (11%) 3 (3%) 0.23 4 (4%) 4 (4%) 0.88
Mother has been to school 162 (82%) 182 (86%) 0.27 78 (81%) 100 (88%) 0.19 84 (82%) 82 (84%) 0.80
Electricity in house 95 (46%) 93 (43%) 0.47 42 (42%) 57 (48%) 0.38 53 (50%) 36 (36%) 0.05
Toilet is outdoor 166 (81%) 172 (79%) 0.68 81 (81%) 93 (78%) 0.60 85 (80%) 79 (80%) 0.94
Rainy  season 86 (41%) 91 (41%) 1.00 40 (39%) 48 (40%) 0.91 46 (43%) 43 (43%) 0.95
Mean  (sd) Mean (sd) p Mean (sd) Mean (sd) p Mean (sd) Mean (sd) p
Weight (kg) 3.24 (0.39) 3.20 (0.37) 0.29 3.24 (0.36) 3.24 (0.39) 0.93 3.23 (0.41) 3.15 (0.33) 0.13
MUAC  (mm) 97 (7) 97 (7) 0.40 97 (7) 96 (8) 0.59 97 (7) 97 (7) 0.53
Head  circumference (cm) 34 (1) 33 (1) 0.41 34 (1) 34 (1) 0.71 33 (1) 33 (1) 0.08
Abdominal circumference (cm) 30 (2) 30 (2) 0.87 30 (2) 30 (2) 0.69 31 (2) 30 (2) 0.55
Length (cm) 49 (2) 49 (2) 0.27 49 (2) 49 (2) 0.35 49 (2) 49 (1) 0.40
Temperature (◦C) 36.8 (0.5) 36.7 (0.6) 0.005 36.9 (0.6) 36.7 (0.6) 0.04 36.8 (0.5) 36.7 (0.7) 0.04
Mother MUAC (mm)  258 (33) 254 (35) 0.23 257 (29) 253 (31) 0.30 259 (37) 256 (40) 0.50
Median Median p Median Median p Median Median p
Mother age 25 (18–34) 24 (18–33) 0.36 27 (18–35) 25 (18–34) 0.46 25 (17–33) 24 (17–32) 0.57
Part  B. At follow-up n (%) n (%) p n (%) n (%) p n (%) n (%) p
Follow-up at 2 weeks 75 (36%) 78 (35%) 0.99 37 (36%) 40 (33%) 0.88 38 (36%) 38 (38%) 0.86
Follow-up at 4 weeks 75 (36%) 81 (37%) 36 (35%) 43 (36%) 39 (36%) 38 (38%)
Follow-up at 6 weeks 59 (28%) 62 (28%) 29 (28%) 37 (31%) 30 (28%) 25 (25%)
Breastfeeding 209 (100%) 221 (100%) – 102 (100%) 120 (100◦%) – 107 (100%) 101 (100%) –
Symptoms 60 (29%) 76 (34%) 0.21 31 (30%) 41 (34%) 0.55 29 (27%) 35 (35%) 0.24
Fever  29 (14%) 31 (14%) 0.96 16 (16%) 17 (14%) 0.75 13 (12%) 14 (14%) 0.71
Cough 43 (21%) 58 (26%) 0.16 20 (20%) 34 (28%) 0.13 23 (21%) 24 (24%) 0.67
Is  doing well 190 (91%) 196 (89%) 0.43 89 (87%) 103 (86%) 0.76 101 (95%) 93 (93%) 0.48
In  vitro cytokines 181 (87%) 197 (89%) 0.42 87 (85%) 107 (89%) 0.39 95 (89%) 90 (89%) 0.78
Differential counts 103 (49%) 109 (49%) 0.99 49 (48%) 61 (51%) 0.59 54 (50%) 48 (48%) 0.67
CRP/RBP measurements 195 (93%) 209 (95%) 0.58 94 (92%) 113 (94%) 0.55 101 (94%) 96 (95%) 0.83
Mean  (sd) Mean (sd) p Mean (sd) Mean (sd) p Mean (sd) Mean (sd) p
MUAC (mm) 117 (12) 116 (13) 0.55 117 (12) 117(13) 0.98 117 (12) 115 (12) 0.32
Temperature (◦C) 36.7 (0.3) 36.7 (0.4) 0.45 36.7 (0.3) 36.7 (0.4) 0.74 36.7 (0.3) 36.7 (0.3) 0.46
Characteristics of the study population at baseline (A) and follow-up (B). Symptoms: fever or cough as reported by the mother or an axillary temperature >37.5 ◦C.
MUAC: mid-upper-arm circumference, used as a marker of nutritional status.
For categorical values, statistical test for difference between randomisation groups by 2 test, alternatively Fisher’s exact test for outcome with levels of ≤5 observations. For
continuous values, test by student’s t-test for normally distributed values, or Kruskal–Wallis for non-normal values. Median is presented with 10 and 90 percentiles. Mean
values  is presented with standard deviation (sd).
In vitro stimulations were only performed after the 18 August 2009. EDTA-treated blood was  only collected after the 7 October 2009. Differential counts were commenced
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f the scatter plot produced by the ABX Pentra60 were repeated
f sufﬁcient amount of blood was available; poor quality analyses
ere excluded.
.8. Measurements of RBP and CRP
From the DBSs, RBP and CRP were measured concurrently by a
ombined simple sandwich ELISA method [8,9]. The samples were
ested in duplicates with the paired baseline and follow-up samples
n the same assay. Samples with a coefﬁcient of variance >20% were
epeated in duplicates.
.9. Statistical analysis
Data was analysed using STATA 12 (StataCorp LP, College
tation, TX, USA).
As in our previous study [4], cytokine outcomes were cate-
orised as below versus above the median, and analysed by Poisson
egression with robust estimate variance providing prevalenceratios (PR) of being above the median in OPV0 + BCG versus BCG
alone recipients. The prevalence of BCG scars or local reactions was
analysed by Poisson regression with robust estimate variance. BCG
scar size was analysed by linear regression.
For every plate analysed on the Luminex instrument, the range
of the cytokine analysis assay was deﬁned by the lower and
upper range of the standard series after censoring for standard
concentrations outside a recovery limit of 80–120% (observed
concentration versus expected concentration). If the lower detec-
tion limit as deﬁned by the manufacturer was higher than the
lower limit inferred from the standard series, the former was
applied. Observations outside this range were considered as non-
detectable.
Cytokine outcomes with >50% detectable measurements were
log-transformed and analysed with Tobit regression to account for
observations below or above the detection range of the Luminex
assay [10]. The estimates were back-transformed to give the geo-
metric mean ratios (GMR) comparing OPV0 + BCG with BCG alone.
Hence, a GMR  or a PR > 1 may be interpreted as OPV increasing
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nig. 2. Prevalence ratio comparing infants vaccinated with OPV + BCG versus BCG a
tratiﬁed by follow-up time. A PR > 1 may  be interpreted as a larger prevalence of h
lone.
he given outcome. Log-transformed haematological data was  ana-
ysed with linear regression using bootstrap to obtain conﬁdence
ntervals (CI). CRP and RBP were analysed by Poisson regression
s the risk of having a CRP measurement >5 g/ml or a RBP level
0.83 mol/l (vitamin A-deﬁcient [11]). RBP was log-normally dis-
ributed and analysed by linear regression. Analyses of follow-up
RP and RBP were adjusted for the respective baseline values.
As the previous observational study had suggested sex-
ifferential effects of OPV on mortality [2], all analyses were
tratiﬁed by sex and follow-up at 2, 4 or 6 weeks, including a test
f effect modiﬁcation on the OPV effect of both sex and follow-up
ime. When analysing all follow-up groups combined, follow-up
ime was adjusted for.
We aimed at enrolling 400 infants (200 OPV + BCG; 200 BCG)
n the immunological study based on preliminary data from the
natural experiment” [4] indicating a signiﬁcant reduction in the
FN- responses to PPD in children receiving OPV0 (n = 250) versus
o OPV0 (n = 150).
. Results
In total, 611 newborns enrolled in the main trial were eligible
or inclusion in the immunological sub-study. Of these, 461 infants
ad a follow-up blood sample taken; valid in vitro cytokine analy-
es were performed on 378 infants, valid differential counts were
vailable for 212 infants, and paired baseline and follow-up mea-
urements of RBP and CRP were obtained from 404 infants (Fig. 1).
he two randomisation groups (OPV0 + BCG versus BCG) did not dif-
er at baseline, except for a slightly, but signiﬁcantly higher mean
emperature in the OPV0 + BCG group (Table 1). At follow-up, the
wo randomisation groups were similar in respect to disease symp-
oms and nutritional status (Table 1). No parasitaemia was found.
verall, the participants included in the immunological analyses
ere similar to the study population enrolled in the main RCT (data
ot shown).r the frequency of in vitro cytokine responders to PPD and BCG above the median,
N- responders among the OPV + BCG recipients than among the recipients of BCG
Blood samples were collected at 2, 4 or 6 weeks after randomi-
sation. For most of the cytokine outcomes, there was a signiﬁcant
effect of follow-up time, in most cases there were increased
cytokine responses with increasing time since vaccination (data
not shown). However, the effect of OPV0 was not signiﬁcantly dif-
ferent at the three follow-up time points (Supplementary Table
1). For all responses to PPD and BCG except IL-10, the difference
between infants vaccinated with OPV0 + BCG versus BCG alone was
most pronounced at 4 weeks after randomisation, although the dif-
ference was small in absolute terms (Fig. 2 and Supplementary
Table 1). Hence, we merged the data, and subsequently analysed
the effect of OPV0 + BCG versus BCG alone adjusting for follow-up
time.
Fewer children who received OPV0 + BCG versus BCG alone had
a high IFN- and IL-5 response to PPD (prevalence ratio (PR): 0.84
(95% CI: 0.72–0.98) and 0.78 (0.64–0.96), respectively) (Table 2).
Analysed as continuous data, the response IL-5 to PPD was sig-
niﬁcantly lower (geometric mean ratio (GMR) of 0.70 (0.51–0.97)
(Supplementary Table 2).
For non-speciﬁc cytokine responses, there was no difference
between infants vaccinated with OPV0 + BCG versus BCG alone
(Table 2 and Supplementary Table 2). Overall, the effect of
OPV0 + BCG was not modiﬁed by sex of the infant apart from the
IL-2 responses to PHA, where OPV0 + BCG was associated with a
reduced prevalence of high responses in males only (Table 2).
We also analysed the effect of OPV0 + BCG on ratios of IFN-
to IL-5 (Th1 versus Th2) and TNF- to IL-10 (pro- versus anti-
inﬂammatory) for outcomes with >50% detectable measurements.
OPV0 + BCG did not affect these ratios (data not shown).
OPV0 + BCG were not associated with the prevalence of having
a BCG scar or local reaction at follow-up, or at 2, 6 and 12 months
of age. There was  no difference in the size of scars. At 12 months,
all infants had developed a BCG scar (Table 3).
OPV0 + BCG was associated with higher neutrophil counts
(GMR: 1.15 (1.01–1.31)). Other haematological values were not
affected (Supplementary Table 3).
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Table 2
Effect of OPV + BCG versus BCG alone at birth on frequency of in vitro cytokine responders above the median, overall and stratiﬁed by sex.
All Male Female p#
obs in n = 378 n = 194 n = 184
Range (%) PR (95% CI) PR (95% CI) PR (95% CI)
OPV IL-2 30 0.90 (0.54–1.50) 0.89 (0.42–1.90) 0.88 (0.44–1.77) 0.97
IL-5  27 0.80 (0.64–1.00) 0.75 (0.54–1.04) 0.85 (0.62–1.16) 0.60
IL-10  66 0.97 (0.79–1.19) 1.01 (0.75–1.35) 0.93 (0.70–1.24) 0.71
IFN-y  37 1.06 (0.79–1.43) 1.29 (0.86–1.93) 0.87 (0.56–1.33) 0.19
TNF-a  28 1.01 (0.78–1.30) 1.16 (0.82–1.65) 0.87 (0.61–1.24) 0.25
BCG IL-2  75 0.85 (0.71–1.01) 0.96 (0.77–1.21) 0.74 (0.57–0.97) 0.14
IL-5  48 0.83 (0.69–1.01) 0.85 (0.65–1.12) 0.81 (0.62–1.07) 0.80
IL-10  84 0.97 (0.80–1.19) 1.06 (0.81–1.38) 0.90 (0.67–1.20) 0.40
IFN-y  78 0.92 (0.80–1.06) 1.04 (0.87–1.24) 0.82 (0.66–1.01) 0.09
TNF-a  72 0.92 (0.79–1.08) 1.03 (0.84–1.27) 0.83 (0.65–1.05) 0.17
PPD IL-2  81 0.93 (0.78–1.10) 1.04 (0.82–1.31) 0.82 (0.63–1.06) 0.19
IL-5  59 0.78 (0.64–0.96) 0.68 (0.50–0.93) 0.88 (0.67–1.16) 0.22
IL-10  93 0.82 (0.67–1.01) 0.81 (0.61–1.07) 0.85 (0.62–1.15) 0.85
IFN-y  78 0.84 (0.72–0.98) 0.84 (0.68–1.03) 0.84 (0.67–1.06) 0.99
TNF-a  75 0.89 (0.74–1.06) 0.96 (0.75–1.24) 0.82 (0.64–1.05) 0.37
Medium3 IL-2  26 0.87 (0.54–1.38) 0.77 (0.42–1.44) 1.03 (0.51–2.11) 0.55
IL-5  30 0.85 (0.69–1.05) 0.84 (0.63–1.13) 0.86 (0.64–1.16) 0.92
IL-10  45 0.98 (0.76–1.26) 0.85 (0.59–1.24) 1.11 (0.78–1.59) 0.30
IFN-y  40 0.77 (0.57–1.03) 0.79 (0.54–1.17) 0.76 (0.48–1.18) 0.88
TNF-a  16 0.84 (0.61–1.16) 0.82 (0.52–1.29) 0.86 (0.54–1.39) 0.87
Medium1 IL-10 46 1.03 (0.83–1.27) 0.87 (0.63–1.21) 1.17 (0.87–1.56) 0.19
TNF-a  56 0.96 (0.78–1.18) 0.83 (0.61–1.14) 1.08 (0.82–1.44) 0.22
PHA IL-2  82 0.90 (0.73–1.10) 0.66 (0.48–0.90) 1.20 (0.90–1.61) 0.01
IL-5  96 0.98 (0.80–1.19) 0.96 (0.72–1.28) 0.99 (0.75–1.31) 0.88
IL-10  98 0.94 (0.77–1.15) 0.97 (0.74–1.28) 0.92 (0.68–1.24) 0.77
IFN-y  96 0.89 (0.73–1.07) 0.90 (0.71–1.15) 0.89 (0.66–1.20) 0.94
TNF-a  86 0.89 (0.73–1.09) 0.96 (0.73–1.27) 0.83 (0.62–1.11) 0.48
Poly  I:C IL-2 43 0.91 (0.65–1.28) 0.76 (0.46–1.25) 1.08 (0.67–1.74) 0.32
IL-5  31 0.88 (0.71–1.08) 0.95 (0.71–1.26) 0.81 (0.60–1.09) 0.44
IL-10  61 0.96 (0.78–1.17) 0.89 (0.68–1.17) 1.06 (0.77–1.46) 0.42
IFN-y  91 1.00 (0.81–1.22) 1.08 (0.83–1.39) 0.94 (0.68–1.30) 0.52
TNF-a  33 0.99 (0.78–1.24) 0.92 (0.68–1.24) 1.11 (0.77–1.59) 0.43
LPS IL-10 98 1.05 (0.86–1.29) 0.92 (0.68–1.24) 1.19 (0.89–1.59) 0.23
TNF-a  85 0.97 (0.79–1.18) 0.94 (0.71–1.24) 1.01 (0.75–1.35) 0.75
Pam IL-10 99 0.96 (0.79–1.18) 0.87 (0.65–1.16) 1.08 (0.80–1.46) 0.29
TNF-a  99 0.94 (0.77–1.14) 0.84 (0.63–1.11) 1.06 (0.80–1.42) 0.24
Prevalence ratio (PR) for the effect of OPV + BCG versus BCG alone at birth on the frequency of individuals responding with in vitro cytokines above the median. Estimates
are  adjusted for follow-up week (time since randomisation). A PR > 1 may  be interpreted as a larger prevalence of high IFN- responders among the OPV + BCG recipients
than  the BCG alone recipients. Estimates of a signiﬁcance p < 0.05 are in bold writing. The frequency of observations within the range of the cytokine measurement assay is
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Test of effect modiﬁcation by sex on the effect of OPV + BCG versus BCG.
Overall, neither CRP nor RBP were affected by OPV (Supplemen-
ary Table 4).
Exclusion of infants with a CRP >5 g/ml (n = 38) resulted
n a slightly stronger association between OPV0 + BCG and the
esponses to BCG and PPD although the effect modiﬁcation was
ot signiﬁcant (Supplementary Table 5).
. Discussion
As hypothesised, co-delivery of OPV with BCG at birth reduced
he IFN- response to BCG vaccination. Also IL-5 responses to PPD
ere reduced by OPV. We  found no effect on BCG scarring; at 12
onths, all infants had developed a scar. OPV was associated with
igher neutrophil counts, but no effects on CRP or RBP levels were
bserved. The study is the ﬁrst RCT demonstrating a heterologous
mmunological effect of OPV0.
. Strengths and limitationsThe trial design allowed us to investigate the effect of
PV0 + BCG versus BCG alone in an unbiased manner. The par-
icipants in the present immunological investigation were a
epresentative sub-group of the overall study population.Whereas the previous observational immunological study of
OPV0 was constrained by comparing OPV0 + BCG to BCG in the
rainy season only [4], the present investigation enrolled infants
over almost a year covering both the rainy (June to November) and
the dry (December to May) season.
The hypothesis in relation to the immune response to BCG was
pre-speciﬁed and it should not be necessary to adjust for multiple
testing. However, the other analyses were exploratory and should
therefore be interpreted with appropriate caution. No placebo was
used in the study. However, the technicians processing the samples
were blinded to the randomisation.
6. Previous studies
Preliminary results from the main trial show that receiving OPV0
was not associated with increased infant mortality, and there was
no signiﬁcant difference in males versus females. Intriguingly, the
effect depended on the age at enrolment; for children enrolled
within the ﬁrst 2 days of life, the hazard ratio for BCG alone versus
OPV0 + BCG was 1.71 (1.11–2.64), while it was 0.82 (0.52–1.30)
for children enrolled at ≥3 days (p for interaction = 0.02) (Lund,
submitted). This stratiﬁcation could not be performed in the
immunological study, however, as too few infants were enrolled
beyond 2 days. Whether the protective effect of early delivery
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of OPV0 may  be mediated via a beneﬁcial immune-programming
could not be corroborated with the immunological markers we here
investigated.
OPV may  reduce, albeit non-signiﬁcantly, rota virus titres and
sero-conversion rate when co-administered with live rota virus
vaccine [12]. A transient suppressive effect of OPV (Sabin type 1)
on tuberculin reactivity was observed decades ago in TB-infected
children receiving chemotherapy. However, OPV  did not impair
the clinical remission of the TB infection [13]. Recently, a “nat-
ural experiment” from Bissau found that OPV0 was  associated
with reduced in vitro IFN- responses to PPD 6 weeks after co-
administration with BCG and lower likelihood of developing a BCG
scar at 2 months [4]. A later similar observational study found that
OPV0 was associated with fewer BCG scars for males but not for
females at 2 months of age [14].
In the present study, virtually all infants have developed a scar
after 6 months, and the size of the local reaction did not differ
between the randomisation groups. The very high scar rate was
higher than the rates reported previously for both BCG + OPV and
BCG alone [4] and may  reﬂect that all infants were BCG vaccinated
by trained nurses at the national hospital with long experience [15].
The results of the present study conﬁrm the previous obser-
vation that OPV attenuates the in vitro responses to PPD, as the
frequency of high IFN- responders and the production of IL-5
to PPD were reduced in infants receiving OPV0 + BCG. Hence, OPV
was associated with a non-biased attenuation of both Th1 and Th2
skewing cytokine responses.
Of note, OPV was  not found to induce leukopenia or lymphocy-
topenia. The observed association of OPV with neutrophil counts
has not been described previously and should be tested in another
study.
The in vitro cytokine responses to OPV stimulation were at
similar or lower levels than the control samples, which is in
line with our previous experiences with the assay (unpublished
data). Relatively low infant cellular responses to polio-antigen have
been reported previously [16]. OPV stimulation may  have had an
inhibitory effect during the incubation. OPV-infected dendritic cells
(DC) are impaired in receptor-mediated endocytosis [17], and it
has been suggested that DC infected with polio are impaired in
the MHC  class I expression [18], although this has been contra-
dicted in a later study [17]. The putatively inhibitory effect of OPV
in culture may  parallel the observed attenuation of BCG responses.
Notably, the immunological interaction is systemic as OPV and BCG
are administered via different routes (oral versus intra-dermal).
The protective effects of BCG against TB is generally lower
in low-income countries [5], and geographical differences in the
immunological effects of BCG has been observed [19]. It could be
speculated that OPV may  contribute to this attenuation of the BCG
effects. Although disputed [20], in vitro IFN- responses to PPD is a
widely used marker of TB immunity [21]. It is not known, however,
how the magnitude of the response early in life is associated with
increased susceptibility later in life [22]. In conclusion, the present
study corroborates that OPV may  have non-speciﬁc effects, as OPV
was associated with a reduced immune response to BCG.
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